Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players Summary GlobalData has released its pharma report, "Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MRSA Market. The report identifies and analyses the key companies shaping and driving the global MRSA market. The report provides insight into the competitive MRSA landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for MRSA - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of MRSA sector through market impact analysis, future market scenario and company analysis Reasons To Buy - Gain a high level view of the trends shaping and driving MRSA market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global MRSA market landscape? Identify, understand and capitalize
Table of Contents
1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles - Current Players 4.3.1 Pfizer 4.3.2 Merck 4.3.3 Allergan 4.3.4 The Medicines Company 4.3.5 Theravance Biopharma 4.3.6 Basilea Pharmaceutica 4.3.7 Sanofi 4.4 Additional Companies with Promising Pipeline Products 4.4.1 Melinta Therapeutics 4.4.2 Cempra Pharmaceuticals 4.4.3 Paratek Pharmaceuticals 4.4.4 Kyorin Pharmaceutical 4.4.5 Nabriva Therapeutics 4.4.6 Debiopharm International 4.4.7 Cellceutix Corporation 5 Appendix 5.1 Bibliography 5.2 Abbreviations 5.3 Methodology 5.4 Forecasting Methodology 5.4.1 Hospitalized MRSA Patients 5.4.2 Percentage of Drug-Treated MRSA Patients 5.4.3 Drugs Included in Each Therapeutic Class 5.4.4 Launch, Label Expansion, and Patent Expiry Dates 5.4.5 General Pricing Assumptions 5.4.6 Individual Drug Assumptions 5.4.7 Generic Erosion 5.4.8 Pricing of Pipeline Agents 5.5 Primary Research - KOLs Interviewed for This Report 5.6 Primary Research - Prescriber Survey 5.7 About the Authors 5.7.1 Author and Therapy Area Director 5.7.2 Author 5.7.3 Epidemiologist 5.7.4 Global Director of Therapy Analysis and Epidemiology 5.7.5 Global Head of Healthcare 5.8 About GlobalData 5.9 Disclaimer
List of Tables
Table 1: Global Sales Forecasts ($m) for MRSA Therapeutics, 2014-2024 Table 2: MRSA Therapeutics Market - Global Drivers and Barriers, 2014-2024 Table 3: Key Companies in the MRSA Marketplace in the 7MM, 2015 Table 4: Pfizer's MRSA Portfolio Assessment, 2015 Table 5: Merck's MRSA Portfolio Assessment, 2015 Table 6: Allergan's MRSA Portfolio Assessment, 2015 Table 7: The Medicines Company's MRSA Portfolio Assessment, 2015 Table 8: Theravance Biopharma's MRSA Portfolio Assessment, 2015 Table 9: Basilea Pharmaceutica's MRSA Portfolio Assessment, 2015 Table 10: Sanofi's MRSA Portfolio Assessment, 2015 Table 11: Companies with Promising Pipeline Candidates for MRSA in the 7MM, 2015 Table 12: Key Historical and Projected Launch Dates for MRSA Across the 7MM Table 13: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM Table 14: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales for MRSA Therapeutics by Country, 2014 and 2024 Figure 2: Global Sales for MRSA Therapeutics by Region, 2014-2024 Figure 3: Global Sales for MRSA Therapeutics by Drug Class, 2014 and 2024 Figure 4: Global Sales for MRSA Therapeutics by Infection Site, 2014-2024 Figure 5: Global Sales for Branded MRSA Products by Company, 2014 and 2024 Figure 6: Company Portfolio Gap Analysis in MRSA, 2014-2024
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected toRead More...
Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing iRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.